缬沙坦治疗慢性心力衰竭合并肾功能不全效果观察被引量：10

导出

摘要目的探讨缬沙坦治疗慢性心力衰竭（CHF）合并轻中度肾功能不全患者的临床疗效.方法将83例心功能Ⅲ～Ⅳ级并轻中度肾功能不全的CHF患者随机分成两组,对照组（43例）应用利尿剂、β受体阻滞剂、洋地黄等常规治疗;观察组（40例）在常规治疗基础上给予缬沙坦治疗.两组治疗前、治疗8周后,双向侧流免疫法测定血清N末端脑钠肽前体（NT-proBNP）;超声心动图测量左心室舒张末期内径（LVEDd）;计算左心室射血分数（LVEF）;乳胶颗粒增强免疫比浊法测量血清胱抑素C（Cys-C）;日立7600自动生化仪检测血清肌酐（Scr）;简化MDRD公式计算肾小球滤过率（GFR）.结果两组治疗8周后,血清NT-proBNP、Cys-C、Scr水平均较治疗前降低,LVEF、GFR升高,P均＜0.05.观察组治疗后比对照组改善显著（P均＜0.05）.结论缬沙坦能显著降低CHF合并轻中度肾功能不全患者的血清NT-proBNP、Cys-C水平,提高LVEF,改善GFR,提升治疗效果.

作者韩利红黄伟刘琮琳

机构地区开封县朱仙镇卫生院郑州大学第一附属医院

出处《山东医药》 CAS 2013年第44期59-61,共3页 Shandong Medical Journal

关键词心力衰竭慢性缬沙坦利钠肽脑胱抑素C

分类号 R541.6 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献8

1Silverberg D, Wexler D, Blum M, et al. The association between congestive heart failure and chronic renal disease [ J ]. Curr Opin Nephrol Hypertens, 2004,13 (2) : 163-170.
2Cannon RO, Schenke WH, Quyyumi A, et aL Comparison of exer- cise testing with studies of coronary flow reserve in patients with mi- crovascular angina[J]. Circulation, 1991,83(5 Suppl) : n[77-81.
3Zhang C, Yasuno S, Kuwahara K, et al. Blockade of angiotensin II type 1 receptor improves the arrhythmia morbidity in mice with left ventricular hvDertronhv[ J]. Circ .1. 2006.70(3) 335-341.
4袁伟杰,边琪.心肾综合征的发病及治疗[J].中国中西医结合肾病杂志,2006,7(6):311-313. 被引量：10
5杨晓君,边娜,李晓峰,赫爱华.丹红注射液治疗心肾综合征33例临床观察[J].山东医药,2011,51(45):78-78. 被引量：12
6金争鸣,胡晓晟,陈君柱,胡申江,张芙荣.慢性心力衰竭患者早期肾损害的临床研究[J].中华内科杂志,2005,44(4):262-264. 被引量：42
7Grubb A. Non-invasive estimation of glomerular filtration rate (GFR). The Lund model : Simultaneous use of cystatin C- and creatinine-based GFR-prediction equations, clinical data and an internal quality check [J]. Scand J Clin Lab Invest, 2010,70(2) :65-70.
8Weinert LS, Prates AB, do Amaral FB, et al. Gender does not influ- ence cystatin C concentrations in healthy volunteers [ J]. Clin Chem Lab Med, 2010,48(3) :405408.

二级参考文献7

1Marenzi G, Lauri G, Guazzi M, et al. Cardiac and renal dysfunction in chronic heart failure: relation to neurohumoral activation and prognosis. Am J Med Sci,2001,321:359-366.
2Marczewski KT, Krawczyk W, Ryszard, et al. Particular fractions of microproteinuria in patients with stabile angina pectoris and without a clinical nephropathy. Med Sci Monit,2000,6:93-95.
3Pittrow D, Wittchen HU, Bramlage P, et al. Nephropathy: an overview for daily practice. Fortschr Med Orig, 2003,121 Suppl 1:39-44.
4Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin Ⅱ antagonists. Kidney Int,2000,57:1803-1817.
5Russo D, Pisani A, Balletta MM, et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis, 1999,33:851-856.
6Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation,2000,102:203-210.
7Smilde TD, Hillege HL, Navis G, et al. Impaired renal function in patients with ischemic and nonischemic chronic heart failure: association with neurohormonal activation and survival. Am Heart J,2004,148:165-172.